Bio-Techne (TECH) Income towards Parent Company (2009 - 2026)
Bio-Techne (TECH) posted quarterly Income towards Parent Company of $51.0 million for Q1 2026, up 125.99% year-over-year from $22.6 million in Q1 2025, and up 34.3% quarter-over-quarter from $38.0 million in Q4 2025.
Analysis
Bio-Techne (TECH) Income towards Parent Company (2009 - 2026) Analysis & Trends
Bio-Techne's Income towards Parent Company history runs 18 years deep, the most recent figure standing at $51.0 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 125.99% year-over-year to $51.0 million; the TTM figure through Mar 2026 stood at $22.7 million (down 71.78% YoY), while the FY2025 annual figure was -$13.4 million, down 111.46% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $51.0 million, up from $38.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $89.7 million in Q3 2022, with the low at -$104.5 million in Q2 2025.
- The 5-year median for Income towards Parent Company is $49.1 million (2024), against an average of $38.0 million.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company jumped 615.95% in 2022, then slumped 899.35% in 2025.
- Bio-Techne's Income towards Parent Company stood at $50.0 million in 2022, then plunged by 45.08% to $27.5 million in 2023, then gained by 27.03% to $34.9 million in 2024, then gained by 8.94% to $38.0 million in 2025, then soared by 34.3% to $51.0 million in 2026.
- Business Quant data shows TECH's Income towards Parent Company at $51.0 million in Q1 2026, $38.0 million in Q4 2025, and $38.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.30 Bn | 11.03 Bn | 211.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.62 Mn |
| Mar 31, 2026 | 51.05 Mn |
| Dec 31, 2025 | 38.01 Mn |
| Sep 30, 2025 | 38.19 Mn |
| Jun 30, 2025 | -68.83 Mn |
| Mar 31, 2025 | 22.59 Mn |
| Dec 31, 2024 | 34.89 Mn |
| Sep 30, 2024 | 33.60 Mn |
| Jun 30, 2024 | 427,000.00 |
| Mar 31, 2024 | 49.06 Mn |
| Dec 31, 2023 | 27.47 Mn |
| Sep 30, 2023 | 50.99 Mn |
| Jun 30, 2023 | 45.69 Mn |
| Mar 31, 2023 | 70.22 Mn |
| Dec 31, 2022 | 50.01 Mn |
| Sep 30, 2022 | 89.73 Mn |
| Jun 30, 2022 | 61.92 Mn |
| Mar 31, 2022 | 60.14 Mn |
| Dec 31, 2021 | 72.06 Mn |
| Sep 30, 2021 | 68.98 Mn |